Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of D.Western Therapeutics Institute, Inc.. A complete text table follows the diagram.
The filing shows early commercial revenue being outweighed by research spending and administrative costs.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Cost of sales | 1 | 17.5M | 10.1% of reported total |
| Gross profit | 1 | 156M | 89.9% of reported total |
| Other and rounding | 1 | 0 | 0.0% of reported total |
| Drug-development sales converted into gross profit | 2 | 173M | Reported six-month total · ¥173M |
| Operating loss | 2 | 309M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 482M | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Cost of sales | Drug-development sales converted into gross profit | 17.5M |
| Gross profit | Drug-development sales converted into gross profit | 156M |
| Other and rounding | Drug-development sales converted into gross profit | 0 |
| Drug-development sales converted into gross profit | Operating costs & expenses | 173M |
| Operating loss | Operating costs & expenses | 309M |